26 matches for your search in the start-up spotlight
rss
Combating menstrual pain through local application of very low doses of painkillers addresses high unmet medical need
25-Mar-2025
Meliodays Medical GmbH, a young pharmaceutical company focusing on the development of a new therapy for the hormone-free and locally acting treatment of menstrual pain, today announces the successful closing of an oversubscribed pre-seed financing round of over 800,000 euros led by capacura GmbH ...
First successful simultaneous 10-target multiplex-screening
09-Jan-2025
QUANTRO Therapeutics, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for ...
A novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood
16-Dec-2024
Lindis Blood Care, a company aiming to set new standards for blood management during cancer surgeries with its medical device CATUVAB®, announced the successful first closing of a follow-on financing round. The new investment will be used to prepare for the anticipated approval of the medical ...
28-Oct-2024
QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company is entering into a strategic research collaboration with the group of Dr. Johannes Zuber, a world-leading expert in functional genetics and one ...
Preparations for upcoming clinical trials in the USA are ongoing
23-Oct-2024
HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the appointment of Dr. Martin Bonde as its new Chair of the Board of Directors, effective immediately. His appointment follows the recent €15 million ...
16-Oct-2024
invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, announced that the company has raised €8.2 million in a Series A fundraising that includes strong participation from existing shareholders and Ligand Pharmaceuticals. Ligand recently acquired APEIRON, the ...
labforward merges with LabTwin
18-Sep-2024
labforward GmbH, a leading provider of solutions for digital transformation in the laboratory with a platform for the digital integration of laboratory equipment and the connectivity of entire workflows consisting of an electronic laboratory journal (ELN, Electronic Lab Notebook) and a laboratory ...
Major advancements in the development of ATL-105 for the treatment of inflammatory lung diseases
25-Jul-2024
AATec Medical GmbH (AATec), a biotech company developing a multi-product platform technology based on recombinant alpha-1 antitrypsin (AAT), provided a company update, reporting on a year of major advancements in unlocking the therapeutic potential of AAT for the treatment of inflammatory ...
AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for up to $1.05 billion
18-Jul-2024
Andera Partners announced that its portfolio company Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, closed its previously announced acquisition by the global pharmaceutical company ...
17-Jun-2024
Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension round was led by new investor Thuja Capital, and as part of the financing, Evan ...
